Lyra Health secured $175 million at a valuation of $2.25 billion if all Series E shares authorized are issued. The digital health platform is previously backed by Adams Street Partners, Tenaya Capital, Meritech Capital Partners, IVP, and Greylock to name a few. The most recent round, Series E, follows $110 million raised for Series D, valuing the company at $1.06 billion. The terms surrounding the Series E include a pari passu liquidation preference with all other preferred, and conventional convertible meaning they will not participate with common stock if there are remaining proceeds. The most recent price per share is $27.4698, an up round from Series D at $14.2140.
Lyra Health is a Prime Unicorn Index component. Here’s how they are currently tracking against the index:
The Prime Unicorn Index provides a unique opportunity for institutional investors to access a fair representation of the private markets where they can make an investment on the future of their portfolios, whether they want to go long or short.
Additionally, the Index provides up-to-date empirical data used to track today’s private capital markets and offer ways to offset exposure in regard to direct private market investments by taking advantage of the trading opportunities presented by Prime Unicorn Index.
Please contact us for information on trading opportunities with the Index.
Bloomberg Ticker: PUNICORN
Reuters Ticker: .PUNICORN